Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
about
Targeting androgen receptor and JunD interaction for prevention of prostate cancer progressionShort-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trialRegulation of p53wt glioma cell proliferation by androgen receptor-mediated inhibition of small VCP/p97-interacting protein expression.Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.Metastatic castration-resistant prostate cancer: critical review of enzalutamide.Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.Surgical stress delays prostate involution in mice.AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.Targets to treat androgen excess in polycystic ovary syndrome.Advances in androgen receptor targeted therapy for prostate cancerKLF4 functions as an activator of the androgen receptor through reciprocal feedback.Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.Enzalutamide: looking back at its preclinical discovery.Development of enzalutamide for metastatic castration-resistant prostate cancer.IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling.The evolving role of enzalutamide on the treatment of prostate cancer.Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer CellsThe safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Revisiting the role of Wnt/β-catenin signaling in prostate cancer.Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.Current treatment strategies for advanced prostate cancer.Connecting androgen receptor signaling and the DNA damage response: Development of new therapies for advanced prostate cancer.Effect of acute mid-intensity treadmill exercise on the androgen hormone level and uncoupling protein-1 expression in brown fat tissue of mouse.Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.Androgen receptor modulation following combination exposure to brominated flame-retardants.Androgen receptor: a potential therapeutic target for glioblastoma.Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis
P2860
Q24339416-AC095DA5-833C-452C-90F4-F44473E6F49AQ27009177-909A2936-9E87-4E19-B56B-AEC0DCBF0502Q30357185-8BD5477B-A7B0-410B-9A96-F26AA5A41C25Q34042831-41AC51A7-3D18-448D-B1D8-65B89FE68E02Q34381852-722D0113-6C8C-4474-83BB-43D93E419E52Q34464312-C89C752A-0076-42C5-B95B-DC2C63D41B60Q34484835-264FD5F1-475A-4CFC-9DE3-90AC54825100Q35040157-6B37CEAC-512C-4FD5-B5DD-F496A845ACB6Q35112392-465F3C88-2A08-4E05-98E0-66C8DA0A7DCDQ35328550-338ECC93-2757-405D-A16D-E0218120FBC3Q35600382-8ACF06BF-A228-453B-8AF3-490CB0B3E959Q35835501-FD52131E-51F1-4CBD-B30C-9504F614E374Q37337217-BC3F3B41-916A-4467-A866-6979480867AAQ37525801-446C047B-581D-4050-B22F-9A4F2A6878CDQ38152744-F7AC8993-0F84-442A-B1CF-FAA808BBF57BQ38211257-36EB6EDE-6EF2-469F-9F73-6A2E9FF4B681Q38589130-FBC2B223-5BA9-4E68-954F-9514D7656385Q38714695-4BE424C4-0CDD-4AFF-8D21-7AE0C9887427Q38720976-5DA91B94-CB92-4ABA-9EB0-ECBA8C7A27A1Q38759678-02764706-58E8-43F2-84CC-E351D4AA50AAQ38841082-A306063D-8F98-4A68-9836-F9F0BDF06F06Q39131794-832EC2D4-92EE-4273-8907-87D077EDBC1BQ47602394-C53DD80C-6816-4667-9008-C05FA139B0CEQ48349923-4325A352-D844-444A-B5C4-D2905894F574Q48561494-0C27BE2E-434F-4774-A372-437193052F93Q52541424-0599AFB9-AADF-4C6D-8609-F58DEA003F53Q53072840-84557122-A7A7-4934-82CD-27A6D469A141Q53614521-033C4E80-9447-40F8-972F-A598C0A8CE8EQ55214081-E632744E-EDD0-42EC-AD6D-7BB98BA8D177Q55259770-E2A36C78-0DFD-4777-A50F-F85085FDCFFEQ58803009-335D4010-7B8A-4D39-B745-6136A133AA45
P2860
Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@en
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@nl
type
label
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@en
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@nl
prefLabel
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@en
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Enzalutamide, an androgen rece ...... ion-resistant prostate cancer.
@en
P2093
Andrew A Protter
Francisco Gómez
Iván E Alfaro
Javier Guerrero
Sebastián Bernales
P2860
P304
P356
10.1002/PROS.22674
P577
2013-06-13T00:00:00Z